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REVIEW
Abstract: Osteoporosis and related fractures are a significant concern for the global
community. As the population continues to age, morbidity and mortality from fractures due
to low bone mineral density (BMD) will likely continue to increase. Efforts should be made
to screen those at risk for osteoporosis, identify and address various risk factors for falls and
associated fractures, ensure adequate calcium and vitamin D intake, and institute
pharmacological therapy to increase BMD when indicated. Agents which increase BMD and
have been shown to decrease fractures, particularly at the hip, should be considered
preferentially over those for which only BMD data are available. Drugs which have been
shown to decrease the risk of age-related osteoporotic fractures include oral bisphosphonates
(alendronate, ibandronate, and risedronate), intranasal calcitonin, estrogen receptor stimulators
(eg, estrogen, selective estrogen receptor modulators [raloxifene]), parathyroid hormone
(teriparatide), sodium fluoride, and strontium ranelate. Data are beginning to emerge supporting
various combination therapies (eg, bisphosphonate plus an estrogen receptor stimulator), though
more data are needed to identify combinations which are most effective and confer added
fracture protection. In addition, further research is needed to identify ideal regimens in special
populations such as nursing home patients and men.
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Background
Epidemiology and economic impact
Osteoporosis, defined as a skeletal disorder characterized by decreased bone strength
and increased susceptibility of fractures (NIH 2001), is a significant health concern
for the international community. Hip fractures, considered to be the most debilitating
fragility fracture secondary to osteoporosis, are associated with an approximately 2-
fold increased risk of mortality the year following the fracture (Center et al 1999;
Empana et al 2004). In 1990 it was estimated that approximately 1.3 million hip
fractures occurred globally (Johnell and Kanis 2004). These fractures were associated
with 740 000 deaths and 1.75 million disability adjusted life-years lost, with the
highest rates occurring in established market economies such as North America,
Japan, Australia, and Western Europe. In the US alone, it is estimated that over 1.5
million fractures occur annually due to osteoporosis, with over 300 000 occurring at
the hip (NOF 2005b).
While hip fractures are considered to be the most debilitating osteoporosis-related
facture, other fracture types are common. In the US, it is estimated that wrist fractures
occur at almost the same rate as hip fractures with approximately 250 000 annually,
and the vertebral fracture rate is more than double that of hip fractures with
approximately 700 000/year (NOF 2005b). These fractures lead to numerous adverse
sequele include chronic pain, deformity, and disability, decreased quality of life,
decreased mobility, increased risk of pressure ulcers, and decreased pulmonary
function (Nevitt et al 1998; Schlaich et al 1998; Lips et al 1999; Fink et al 2003;
Margolis et al 2003; Hallberg et al 2004).
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As the global population ages, the prevalence of age-
related osteoporosis (ie, postmenopausal osteoporosis, male
osteoporosis) and related fractures is likely to increase
considerably. In the US, the prevalence of osteoporosis is
expected to grow from an estimated 10 million in 2002 to
14 million by 2020 (NOF 2005a). In the EU, the total number
of hip fractures is estimated to increase from 414 000 to
972 000 from year 2000 to 2050 (Compston et al 1998).
Vertebral fractures are estimated to increase during this time
from 23.7 million to 37.3 million.
The economic consequences of osteoporosis with its
associated morbidity and mortality due to fractures are
staggering. While total world-wide estimates are not readily
available, there are data that describe the costs in various
countries. In Belgium (population ~10 million), the total
cost of hip fractures in 1996 was almost US$126.2 million
per year (Reginster et al 1999). The estimated cost of
osteoporotic fractures in females greater than 50 years of
age using 1997 figures cost the UK £727 million (US$1.23
billion); or an estimated £942 million (US$1.6 billion)
including men, assuming the cost of treatment was the same
as females (Dolan and Torgerson 1998). The annual cost of
osteoporotic fractures to the US healthcare system in 2001
was approximately US$17 billion, with a single hip fracture
costing approximately US$40 000 (NOF 2004).
Diagnosis and classification
The gold standard for diagnosis of osteoporosis is
measurement of bone mineral density (BMD) using central
dual-energy x-ray absorptiometry (Lewiecki et al 2004).
Bone mineral density is defined as the average concentration
of mineral per unit of area (g/cm
2) measured (Cummings et
al 2002). This figure is then reported as the number of
standard deviations (SD) between the value of an individual
and the mean value for a reference population. The World
Health Organization (WHO) classification for diagnosis is
based on comparison of BMD to a young-adult mean (T-
score) for postmenopausal women and men >50 years.
Normal is considered a T-score greater than –1.0, osteopenia
is a T-score between –1.0 and –2.5, and osteoporosis is a T-
score less than –2.5. Severe osteoporosis may be considered
when the T-score is less than –2.5 in the presence of one or
more fragility fractures (Kanis and Gluer 2000). For
children, premenopausal women, and men younger than 20
years, Z-scores, which are SD comparisons based on age
and gender, should be used instead rather than T-scores
(Lewiecki et al 2004). Because BMD declines with age, T-
scores are lower than Z-scores, particularly for patients with
advanced age. For instance, a 70 year old female with a Z-
score of –1.0 may have a T-score of –3.0 and thus be
considered osteoporotic.
Bone mineral density is a surrogate marker for bone
strength and fragility fractures. It is estimated that BMD
accounts for approximately 70% of bone strength (NIH
2001) and correlates well with fracture risk. For every 1 SD
decline in femoral-neck BMD it is estimated that the risk of
an osteoporotic fracture at the hip increases by 2.5-fold
(Cummings et al 1993; Marshall et al 1996). While BMD is
useful to evaluate risk of fracture, it should be noted that a
significant portion of bone strength may be derived from
other sources (eg, genetics). Thus, while BMD is a useful
tool to evaluate risk of osteoporotic fractures, choice of
medication used for prevention or treatment should ideally
be based on data demonstrating reduction in fractures,
recognizing that other factors such as past medical history
and adherence may also play a role.
Risk assessment and prevention of
fractures
To identify patients at risk of fractures and optimize
pharmacotherapy, a thorough risk factor analysis is
recommended. Two major areas of risk factor assessment
that should be considered, particularly for older individuals,
include an assessment of both “bone” and “non-bone”
related risks. “Bone-related” risk factors are those factors
associated with bone density. “Non-bone” risk factors are
variables associated with fracture risk unrelated to bone
density, and may increase fracture risk irrespective of
osteoporosis diagnosis. However they compound the risk
of an osteoporosis end-point in a patient who has decreased
bone density.
Traditional risk factor assessment focuses on “bone”
related factors. These are variables that increase the risk of
fracture by affecting BMD and include physical frame,
genetics, lifestyle, hormonal changes, and medication effects
(NOF 2004). Prior to obtaining BMD measurements, a full
assessment of these “bone” related risk factors should
include complete medical history including family history
of osteoporosis and fracture and any personal history of
fracture as an adult. For women, this should include a
gynecological history including history of menses,
pregnancies, surgeries, or menopause. Physical exam should
reveal weight, height (particularly if height has changed from
known adult maximum) and curvature of the spine. Patient
interview can reveal diet (including dairy and supplemental
calcium/vitamin D intake), exercise, smoking, alcohol use,Therapeutics and Clinical Risk Management 2006:2(3) 283
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and current medication use. Tools such as the Osteoporosis
Risk Assessment Instrument (ORAI) and the Simple
Calculated Osteoporosis Risk Assessment (SCORE) are
validated instruments which take into account these
“traditional” risk factors (Lydick et al 1998; Cadarette et al
2000). It has also been reported that the WHO will soon
release an instrument to quantify the contribution of various
osteoporosis risk factors and calculate an individuals’
anticipated 10-year fracture risk (Tucci 2006).
In addition to traditional risk factor assessment,
clinicians should be mindful of additional “non-bone” risk
factors. While these variables are not directly related to bone
density, they can increase risk of fractures by increasing
the risk of fall-related injury. Fall-related injuries are a
leading cause of morbidity and mortality in older individuals.
While falls can cause a range of injuries not limited to
fracture, including pain, swelling, bruising, lacerations,
sprains, concussions, or subdural hematomas, the combined
risk of falls and low BMD puts older individuals at particular
risk of functional decline due to fracture. In the US, falls
are a significant cause of admission to long term care
facilities, and are a leading cause of both injury and death
in older individuals (Granek et al 1987; Tinetti and Williams
1997).
While only 5%–10% of falls in the community setting
result in fracture and subsequent hospitalization (van Weel
et al 1995), this percentage is magnified by the sheer
prevalence of falls. It has been estimated that one third of
community dwelling individuals over the age of 65 will fall
in one year (Tinetti and Williams 1997; Cumming 1998).
This estimate increases to 50% when considering the
population over the age of 85 years.
It may be difficult to elucidate the cause and effect
relationship between falls and fractures. While fractures can
certainly result from a fall, the fall can likewise be a
consequence of a fracture. This can occur when a pathologic
fracture of the hip is the precipitating cause. If there is no
clear patient history to shed light on circumstances
surrounding a fall event, it may be difficult to determine
which event, the fall or the fracture, preceded the other. For
that reason, both “bone” and “non-bone” risks for fracture
should be assessed in all older individuals. Risk factors for
falls can be generally categorized as intrinsic or extrinsic as
described in Table 1 (Sleeper et al 2000).
A component of both bone and non-bone risk factor
assessment that deserves special attention is the drug
regimen review including: 1) medications for the prevention
or treatment of osteoporosis, 2) medications associated with
drug-induced osteoporosis, and 3) medications or
environmental factors predisposing to falls. Other areas
which may be evaluated include whether a BMD evaluation
has been performed, intake of calcium and vitamin D, as
well as their respective formulations, doses, and
administration regimens. While the presence of an
osteoporosis treatment regimen suggests a BMD evaluation
has occurred, it should not be assumed that fracture risk has
been optimally managed. The presence of pharmacotherapy
for an established osteoporosis diagnosis is in fact a
surrogate marker that indicates the need for ongoing
assessment of both bone and non-bone related risk.
Medications associated with drug-induced osteoporosis such
as glucocorticoids, chronic heparin, excessive thyroid
replacement, immunosuppressants, or anticonvulsants can
also be identified (NOF 2004). Concurrent medications may
also be important non-bone risk factors for falls. Medications
traditionally associated with fall risk include psychoactive
medications (eg, antipsychotics, antidepressants,
benzodiazepines, sedative hypnotics), opioids, nonsteroidal
antiinflammatory drugs (NSAIDs), anticholinergic
medications, and cardiovascular medications (Kannus et al
2005). Mechanisms by which these agents can cause falls
include sedation, dizziness, cognitive impairment, ataxia,
Table 1 Intrinsic and extrinsic risk factors for fall-related fractures
Intrinsic risk factors Sensory Visual impairment, vestibular disorders, peripheral neuropathy
Musculoskeletal Muscle weakness, pain, gait/balance disturbances, range of motion, endurance
Behavioral–cognitive Cognitive impairment, depression, impaired daily activities, fear of falling
Medication-related Antipsychotics, antidepressants, benzodiazepines and other sedative hypnotics, Narcotics,
NSAIDs, anticholinergic medications, cardiovascular medications, and the use of multiple
medications
Disease-state related Parkinson’s Disease, Alzheimer’s disease, stroke, depression, arrhythmias, hypoglycemia,
orthostatic hypotension, seizures, glaucoma, syncope, mobility dependence, history of falls
Extrinsic risk factors Environment Steps or unmarked floor rises, uneven or loose carpeting, obstacles in path, low light or
excessive glare, ill-fitting footwear
Activity Need for or inappropriate use of assistive devices, “furniture cruising”
Abbreviations: NSAIDs, nonsteroidal antiinflammatory drugs.Therapeutics and Clinical Risk Management 2006:2(3) 284
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blurred vision, agitation, extrapyramidal movements,
psychomotor slowing, orthostatic hypotension, increased
postural sway, arrhythmias, and delirium. Drug regimen
review should reveal not only the presence of a potentially
problematic drug, but the daily dosage, frequency and
duration of use, and cumulative number of high-risk agents.
Optimal management of various comorbidities which may
increase the risk of dizziness or instability (eg, prevention
of hypoglycemic episodes in patients with diabetes) may
decrease the risk for fall-related fractures.
Pharmacological treatment
Pharmacological goals for osteoporosis include halting bone
loss, improvement of BMD, and reduction in fragility
fractures. Whenever possible, drug therapies that have been
shown to decrease fractures, particularly at the hip, should
be used as hip fractures have the greatest impact from a
patient and societal perspective (Figure 1).
Bone remodeling involves both resorptive and anabolic
processes. Drugs that have traditionally been used for the
treatment of osteoporosis have largely focused on inhibition
of bone resorption. More recently however, medications
which stimulate bone formation or that both inhibits
resorption and stimulate anabolic processes have been
developed or are under investigation.
Calcium and vitamin D
Adequate intake of both calcium and vitamin D are an
essential part of osteoporosis prevention, and no treatment
regimen should be considered complete without these
adjunctive therapies. There are numerous studies that have
reported outcomes of supplemental calcium, vitamin D, or
both on BMD and fractures (Table 2).
Calcium
The majority of the body’s calcium is stored in bone, and as
such, is the primary source when dietary sources are
insufficient. For this reason, adequate calcium intake is a
first-line defense against bone loss. A variety of calcium
regimens have been studied to assess the effects on BMD
and fractures (Table 2). While not every evaluation of
calcium has consistently demonstrated a clear reduction in
fracture risk, guidelines recommend 1000–1500 mg
elemental calcium daily, whether from diet or from
supplements (NIH 1994; NAS 1997; NOF 2004), with
higher doses (eg, 1200–1500 mg) for those greater than 50
years or who have low BMD.
Vitamin D
Vitamin D is an essential component that, along with
parathyroid hormone (PTH), regulates serum calcium
concentrations. Inadequate vitamin D intake may be a
greater concern than poor calcium intake, as vitamin D may
not be as prevalent in the diet as calcium, and patients may
be less aware of vitamin D requirements than calcium. In
addition, low exposure to sunlight and poor renal function
may also lead to decreased concentrations. Yet supplemental
vitamin D, with or without calcium, has been shown to
reduce fracture rates and may also have effects on muscle
strength and risk of falling. A recent meta-analysis of double-
blinded, randomized controlled trials evaluating various
doses of vitamin D found that while lower doses (eg, 400 IU)
were not associated with a significant benefit, 700–800 IU
daily was associated with 26% reduction in hip fractures
(number needed to treat [NNT]=45) and 23% reduction in
nonvertebral fracture (NNT=27) when compared with
calcium alone or placebo (Bischoff-Ferrari et al 2005).
Recently, the investigators for the Women’s Health Initiative
released results of a 7 year follow up of over 30 000 women
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Figure 1 Fracture reduction data available by agent and site.
Note: Please see text for discussion of studies demonstrating fracture
reduction and references.Therapeutics and Clinical Risk Management 2006:2(3) 285
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aged 50–79 (Jackson et al 2006). Despite a 1.06% increase
in BMD, this study did not show a statistically significant
reduction in hip fractures among women who received
1000 mg calcium carbonate and 400 IU vitamin D3, and a
17% increase in risk of renal calculi. However, there are
several important points that should be noted about this
study. In addition to the use of a daily dose of vitamin D
lower than currently advocated, the average T score at
baseline was normal (–0.65). Only 3% of subjects for whom
bone density was measured at baseline had a T score below
–2.5. In addition, it was noted that the reduction in hip
fracture risk was statistically significant after non-adherent
patients were excluded.
Vitamin D supplementation, particularly with the active
form (ie, calcitriol) may be theoretically important for frailer,
institutionalized individuals or those with chronic health
conditions (eg, PTH disorders, chronic renal failure, and
dialysis) due to the inability or reduced capacity to convert
vitamin D to the active form. Clinical trials with calcitriol
evaluating BMD and fracture outcomes have had mixed
results. However, in one trial of 50 women with vertebral
fractures, spinal BMD increased 1.94% after 2 years of
treatment with calcitriol 0.62 mcg/day plus 1000 mg calcium
versus a 3.92% decrease for placebo (p=0.001) (Gallagher
and Goldgar 1990). In another trial of 622 women with
compression fractures, 0.25 mcg calcitriol BID given for 3
years to women with a history of ≤5 fractures decreased the
rate of new vertebral fractures compared with 1000 mg
calcium alone (4.2 vs 31.0 fractures per 100 patient years,
p<0.0001) (Tilyard et al 1992). In both of these studies,
serum or urine calcium monitoring was necessary to identify
subjects requiring dose adjustment due to hypercalcemia or
hypercalcuria. Moreover, the true benefit of calcitriol over
other vitamin D-containing agents has not been established,
and activated vitamin D has not been evaluated against first
line therapies such as bisphosphonates. Therefore, further
data is needed before the optimal place of calcitriol in
osteoporosis therapy is established.
Monitoring of serum vitamin D concentrations is
intriguing, and has been suggested as a means of clinically
identifying individuals in need of additional supplementation
(Holick et al 2005). The reported range of normal values
may vary by laboratory, but is typically 16–120 ng/ml
(Wallach 1986). Opinion varies as to the threshold for
deficiency, but on average is around 15 ng/ml (LeBoff et al
1999). Various studies have demonstrated that deficiency
of vitamin D is associated with decreased BMD and
increased fractures (Aaron et al 1974; Bischoff-Ferrari et al
2004). It is also clear that vitamin D supplementation confers
benefit with respect to both BMD and fracture risk (Bischoff-
Table 2 Clinical trials of calcium and vitamin D
Authors/year Study design Intervention Outcomes NNT
Chapuy et al 1992 32 70 postmenopausal women 1200 mg elemental calcium 43% reduction in hip fracture 56
(mean age 84)  (calcium triphosphate) (p=0.043)
800 IU vitamin D given for 18 months 32% reduction in nonvertebral 29
fractures (p=0.015)
Dawson-Hughes 389 ambulatory men and 500 mg of calcium (calcium citrate) 50% reduction in nonvertebral 14
et al 1997 women >65 years plus fractures (p=0.02)
700 IU vitamin D3 daily for 3 years
Grant et al 2005 5292 elderly men and 1000 mg calcium (calcium carbonate), NS (high rate of non-compliance)
women (mean age 77 years) 800 IU vitamin D3, the combination,
with history of low trauma or placebo for 45 months
fracture  
Shea et al 2002 Meta-analysis of 15 trials Various formulations of calcium 2.1% increase in total body NS
totaling 1806 patients ranging from 500–2000 mg (two BMD23% decrease in vertebral
studies contained vitamin D fractures (95% CI 0.54–1.09)
supplementation, 400 IU daily 14% decrease in nonvertebral NS
or 300 000 IU at study start). fractures (95% CI 0.43–1.72)
Average follow-up = 2 years
Jackson et al 2006 36 282 women aged 50–79 1000 mg calcium (calcium carbonate), 1.06% increase in BMD (p<0.01) NS
with average baseline 400 IU vitamin D3 for 7 years Non-significant reduction in hip
T score of −0.65 (+/−1.03) fracture in primary analysis;
29% reduction in hip fracture
among adherent subjects
(95% CI 0.52–0.97).
Abbreviations: BMD, bone mineral density; CI, confidence index; NNT, number needed to treat; NS, not significant.Therapeutics and Clinical Risk Management 2006:2(3) 286
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Ferrari et al 2005). However, it is not clear if laboratory
assessment is routinely necessary or cost effective in all
patients. Monitoring may be useful in those individuals for
whom severe deficiency or coexisting hyperparathyroidism
is suspected. For instance, several studies have demonstrated
improvements in elevated PTH concentrations in patients
with established vitamin D deficiency who receive
supplemental vitamin D (Malabanan et al 1998; Need et al
2004). However, while studies evaluating the efficacy of
vitamin D for osteoporosis often report data regarding
subjects’ 25-hydroxyvitamin D levels, not all studies
consistently report an association between the change in
serum level and the amelioration of fracture risk (Lips et al
1996; Dawson-Hughes et al 1997; Adams et al 1999; Jackson
et al 2006). Further, an optimal target vitamin D
concentration has not been universally established. Despite
this, there is sufficient evidence to recommend vitamin D
supplementation as a routine part of osteoporosis prevention
and treatment (Bischoff-Ferrari et al 2005). Therefore, an
individual patient’s eligibility for such therapy should not
be contingent upon laboratory assessment of deficiency.
Product recommendations
As the quantities and formulations of calcium or vitamin D
products have varied from study to study, there is currently
no clear consensus which agent or regimen should be
recommended to all patients. Based upon preponderance of
data from multiple studies, a total daily intake of 1200–
1500 mg calcium and 600–800 IU of vitamin D is
recommended for those with age-related osteoporosis or who
are at risk. As these total daily doses can be achieved by a
variety of products, clinicians need to be prepared to answer
questions regarding product selection. Patients should be
counseled that the recommended daily amount of calcium
refers to the elemental form, and this may vary depending
upon the form chosen (Table 2). Second, there are potential
concerns regarding bioavailability of various formulations
based upon gastric absorption. It has been suggested that
acid-dependent forms of calcium, such as calcium carbonate,
are not as efficiently absorbed as acid-independent forms,
such as calcium citrate. The clinical significance of this has
not been clearly determined but may be worth considering,
particularly in patients with age-related changes in gastric
pH or who are on acid suppression therapy. Regardless of
formulation selected, patients should also be counseled that
bioavailability can be maximized by administering calcium
supplements in divided doses, limiting intake at a single
dosing interval to 500–600 mg, and giving with meals,
particularly with calcium carbonate. The administration
intervals of calcium supplements should also be timed so
as to avoid absorption interactions with other products such
as iron salts, fiber laxatives, quinolones, or tetracyclines.
Bisphosphonates
The bisphosphonates are a first line therapy for most patients
with age-related osteoporosis. The nitrogen-containing
bisphosphonates alendronate, risedronate, and ibandronate,
are the most common agents used for treating and preventing
age-related osteoporosis. While other bisphosphonates are
available (eg, etidronate, pamidronate, tiludronate, and
zoledronic acid) for other indications (eg, Paget’s disease,
hypercalcemia of malignancy, corticosteroid-induced
osteoporosis), these agents are not first-line therapy for age-
related osteoporosis (Licata 2005).
The nitrogen-containing bisphosphonates increase BMD
by inhibiting several key enzymes in the mevalonate
pathway (Licata 2005). This leads to increased BMD
through several antiresorptive mechanisms including
inhibition of osteoclast recruitment, osteoclast activity on
the bone, induction of osteoclastic apoptosis, and alteration
of the bone or bone mineral to reduce dissolution rate.
Through inhibition of bone resorption, the bisphosphonates
increase BMD approximately 2%–8% depending upon the
agent, dose, and site measured and are effective for both
the prevention and treatment of age-related osteoporosis
(Cummings et al 1998; Harris et al 1999; Black et al 2000;
Orwoll et al 2000; Reginster et al 2000; McClung et al 2001;
Chesnut et al 2004).
Table 3 Characteristics of various calcium preparations. Data
from Wickersham and Novak (2002)
Calcium % elemental Elemental calcium Absorption
salt calcium in example dosage acid
forms dependent
Carbonate 40% 1500 mg tablet Yes
contains 500 mg 
Triphosphate 39% 1565.2 mg tablets Yes
contain 600 mg
elemental calcium
Citrate 21% 950 mg tablets No
contain 200 mg
elemental calcium
Lactate 13% 650 mg tablets No
contain 84.5 mg
elemental calcium
Gluconate 9.3% 500 mg tablets No
contain 45 mg
elemental calciumTherapeutics and Clinical Risk Management 2006:2(3) 287
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Alendronate is an oral bisphosphonate that has been
shown to decrease both vertebral and non-vertebral
fractures. In the Fracture Intervention Trials (FIT), the effects
of alendronate 5 mg daily for 2 years followed by 10 mg
daily for 2 years in women with low BMD and no history
of fracture or at least one-vertebral fracture was assessed.
In the arm of the trial that included women with at least one
prior vertebral fracture, 2027 women were followed to assess
the risk of new vertebral and nonvertebral fractures (Black
et al 2000). After an average follow-up of 2.9 years,
alendronate increased BMD at the femoral neck 4.1%, total
hip 4.7%, and posterior–anterior lumbar spine 6.2%
compared with placebo (p<0.001 for all) and decreased the
risk of new radiographic fractures by 47% (NNT=14),
clinical vertebral fractures 55% (NNT=37), hip fractures
51% (NNT=91), wrist fractures 48% (NNT=53), and any
non-vertebral fracture by 20% (NNT=36; p<0.05 for all).
In the FIT arm that included women with low BMD but
without a prior history of fracture, 4432 women were
followed for an average of 4.2 years (Cummings et al 1998).
At the end of the study, alendronate increased BMD at the
femoral neck 4.6%, total hip 5.0%, and lumbar spine 6.6%
compared with placebo (p<0.001 for all) and decreased the
rate of any clinical fracture by 36% (NNT=15), though this
effect was only significant in patients with osteoporosis at
baseline (initial femoral neck T-score ≤–2.5). Alendronate
decreased the rate of radiographic vertebral fractures overall
by 44% (NNT=60).
Vertebral and non-vertebral fracture data is available for
risedronate. In the Vertebral Efficacy with Risedronate
Therapy in North American (VERT-NA) and Multi-National
(VERT-MN) studies, the effects of risedronate 2.5 mg daily
and 5 mg daily for 3-years was compared with placebo in
postmenopausal women with osteoporosis and prior
vertebral fractures (Harris et al 1999; Reginster et al 2000).
After 3 years, risedronate 5 mg daily decreased the rate of
new vertebral fractures similarly in the two studies; 41%
(NNT=10) and 49% (NNT=20) in the VERT-NA and VERT-
MN studies respectively. Nonvertebral fractures were
reduced in the VERT-NA study 40% (NNT=31) and 33%
(NNT=20; p=0.06) in the VERT-MN trial.
Risedronate has also been studied in patients at very high
risk for fracture. In the Hip Intervention Program (HIP)
study, the effects of risedronate 2.5 mg or 5 mg daily in 5455
elderly women with osteoporosis (femoral neck T-score <–
4 or <–3 plus a non-skeletal risk for falls) was compared
with placebo (McClung et al 2001). After mean follow-up
of 2.3 years, risedronate decreased the overall rate of hip
fracture 30% (NNT=90), 40% in women 70–79 years of
age (NNT=77), and 60% in those 70–79 years of age with
at least 1 vertebral fracture at baseline (NNT=29).
Ibandronate, an oral bisphosphonate with an extended
dosing interval, is the newest agent in this class to be
approved for both the prevention and treatment of
postmenopausal osteoporosis. In the oral ibandronate
osteoporosis vertebral fracture trial in North America and
Table 4 Approved drug regimens in the US and EU for management of osteoporosis
Drug regimen Prevention of Treatment of Treatment of
(Listed alphabetically by class) postmenopausal postmenopausal male
osteoporosis osteoporosis osteoporosis
Bisphosphonates
Alendronate 
5 mg PO daily or 35 mg PO once weekly X
10 mg PO daily or 70 mg PO once weekly X X
Ibandronate
2.5 mg PO daily or 150 mg PO once monthly X X
Risedronate
2.5 mg PO daily or  X
5 mg PO daily or 35 mg PO once weekly X
Calcitonin 200 IU intranasally once daily X
Estrogen receptor stimulators
Estrogen replacement therapy  X
(various dosage forms)
Raloxifene 60 mg PO daily X X
 Tibolone  2.5 mg PO dailya Xa
Teriparatide (PTH 1-34) 20 mcg subcutaneous daily X X
Strontium ranelate 2 g PO dailya Xa
Note: aNot approved in the US.
Abbreviations: PO, by mouth; PTH, parathyroid hormone.Therapeutics and Clinical Risk Management 2006:2(3) 288
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Europe (BONE) study, ibandronate 2.5 mg daily or 20 mg
every other day for 12 doses every 3 months was compared
with placebo in 2946 osteoporotic women with 1–4 prior
vertebral fractures (Chesnut et al 2004). After 3 years,
vertebral fractures were significantly reduced 62%
(NNT=20) and 50% (NNT=21) respectfully for the daily
and intermittent doses compared with placebo. Ibandronate
did not decrease clinical non-vertebral factures or hip
fractures. However, a possible reason for this lack of benefit
was the relatively high femoral neck T-score of patients at
baseline (mean T-score –2.0). Post hoc analyses of patients
at greater risk for hip fracture (ie, femoral-neck T-scores <–
3.0) demonstrated that daily ibandronate was effective in
decreasing nonvertebral fractures by 69%.
Traditionally, oral bisphosphonates had been given on a
daily basis. More recently however, intermittent regimens
(eg, once weekly with alendronate and risedronate and once
monthly with ibandronate) have been developed in an
attempt to increase patient adherence. It is important to note
that fracture data are not available for these intermittent
regimens, though studies are available that have
demonstrated equivalent effects on BMD compared with
daily dosing (Brown et al 2002; Rizzoli et al 2002; Miller
et al 2005). However, while fracture data are not specifically
available for these intermittent regimens, data are beginning
to emerge that suggest these regimens do increase patient
adherence. In an administrative claims study of 30 health
plans, once weekly bisphosphonate use was associated with
greater medication persistence than once daily users (69%
vs 58%, p<0.001) and had higher rates of retention on
treatment (44% vs 32%) at one year of use (Cramer et al
2005). However, it is important to note that long-term
adherence (eg, 1 year) was still very poor with these
intermittent regimens. Thus, continued research on
modalities to increase patient adherence to osteoporosis
therapies is warranted.
Calcitonin
Calcitonin is a 32-amino acid peptide that can be obtained
from numerous animals, including a human form through
recombinant technology. However, salmon calcitonin is the
most potent and therefore most frequently used isolate (Zaidi
et al 2002). The primary effect of calcitonin is to decrease
bone resorption by inhibiting the function of mature
osteoclasts. Calcitonin works via both cAMP and calcium-
dependent pathways to accomplish this effect (Zaidi et al
2002).
There are data supporting the efficacy of nasal calcitonin
in reducing vertebral fractures, however non-vertebral
fracture data is lacking. The prevent recurrence of
osteoporotic fractures (PROOF) study consisted of 1255
postmenopausal women with pre-existing vertebral fractures
who were randomized to 200 IU of intranasal salmon
calcitonin or placebo (Chesnut et al 2000). Patients were
followed for a total of five years to assess incidence of new
vertebral fractures. The calcitonin group had a 33%
reduction in the risk of vertebral fractures (NNT=33)
compared with placebo.
In addition to antiresorptive properties, calcitonin has
also been shown to be effective for managing the pain
associated with acute vertebral compression fractures
(Lyritis et al 1991). Thus, this agent may be useful in patients
who have experienced a recent osteoporosis-related
vertebral fracture. However, there are limitations with use
of this agent. First, data regarding antifracture efficacy is
significantly less when compared with other agents used
for osteoporosis. Secondly, data are available that suggest
the antiresorptive effects of calcitonin may diminish
significantly with time. Between 19–26 months, a plateau
effect has been demonstrated, which is likely due to down-
regulation of calcitonin receptors (Gruber et al 1984). Thus,
due to the availability of agents with more favorable fracture
data, particularly when used long-term, calcitonin should
not be a first line agent in the treatment of osteoporosis.
Estrogen receptor stimulators
Stimulation of estrogen receptors is another method by
which BMD may be increased. Agents which stimulate
estrogen receptors include estrogen (various forms),
selective estrogen receptor modulators (SERMs), and
tibolone. Estrogen receptors are located in various tissues
throughout the body, including breast, uterine, intestinal,
and bone tissues. In bone tissue estrogen receptors are
located on osteoblasts and osteoclasts, and stimulation of
these receptors by estrogen decreases osteoclast activity,
thereby decreasing bone resorption. In addition, estrogen is
also associated with peripheral inhibition of PTH, increased
intestinal absorption of calcium, and decreased renal
excretion of calcium (Notelovitz 1997).
Estrogen
Estrogen, with or without a progesterone, has beneficial
effects on surrogate markers of bone turnover and on fracture
risk, and has been used extensively for the prevention ofTherapeutics and Clinical Risk Management 2006:2(3) 289
Management of age-related osteoporosis
osteoporosis. There is evidence that estrogen increases BMD
at the hip, lumbar spine, and peripheral body sites (Wells et
al 2002). However, there has been relatively less data with
respect to fracture outcomes. In 2 meta-analyses of 13 and
22 trials, estrogen was associated with an overall 13%
reduction in vertebral fracture and a 27% reduction in non-
vertebral fractures respectfully (Torgerson and Bell-Syer
2001a, 2001b).
Two large, randomized, placebo controlled trials, the
Heart and Estrogen/Progestin Replacement Study (HERS)
and the Women’s Health Initiative (WHI), evaluated the
combination of estrogen plus progestin (Hulley et al 1998;
WGWHII 2002; WHISC 2004). The HERS and its open
label follow-up HERS II (Cauley, Black, et al 2001) did not
report a reduction in fractures for hip, wrist, vertebral or
total fractures (hazard ratio [HR] 1.04, 95%CI 0.87–1.25).
The WHI was a much larger study evaluating 0.625 mg
conjugated equine estrogen (CEE) plus 2.5 mg
medroxyprogesterone acetate versus placebo (WGWHII
2002). The estrogen-only arm evaluated 0.625 mg daily CCE
or placebo in women with a hysterectomy (WHISC 2004).
In the estrogen plus progesterone arm, there was a 33%
reduction (NNT=345) in the risk of hip fracture (Cauley et
al 2003). The reduction in hip fracture risk was greater for
those individuals receiving estrogen plus progesterone who
also received at least 1200 mg of daily calcium at baseline.
Estrogen plus progesterone was also associated with a 36%
reduction in vertebral fractures (NNT=387), and a 30%
reduction in lower arm/wrist fractures (NNT=125). The
results of the estrogen-only arm likewise decreased the risk
of hip and vertebral fractures slightly (NNT=216 and
NNT=225 respectively).
Despite the benefit of hormone replacement therapy for
osteoporosis, there are many concerns with chronic use. The
estrogen plus progesterone arm of the WHI was stopped
after an average follow-up of 5.2 years due to increased
risk of breast cancer (number needed to harm [NNH]=237).
Safety analysis also revealed a slight increase in risk of
coronary heart disease events (NNH=237), pulmonary
embolism (NNH=227), stroke (NNH=225), and deep vein
thrombosis (NNH=141). Similar results were reported in
the estrogen-only arm of the WHI, which was stopped after
an average follow-up of 6.8 years. While there did not appear
to be an increased risk of breast cancer or pulmonary events,
there was no benefit reported for the primary outcome of
coronary heart disease events (CHD) and an increased risk
of stroke (NNH=125) and deep vein thrombosis
(NNH=220).
Based on findings from the WHI, HERS, and other meta-
analyses of estrogen or estrogen plus progestin, the 2005
US Preventive Services Task Force (USPSTF)
recommended against routine use of estrogen with or without
a progestin for the prevention of chronic conditions in older
women (USPSTF 2005). While citing good evidence for
increased BMD, and fair to good evidence for reducing
fracture risk, the task force concluded that the risk of breast
cancer, venous thromboembolism, CHD, stroke, and
cholecystitis “likely to exceed the chronic disease prevention
benefits in most women.” After the completion of the
estrogen-only arm of the WHI, the task force updated its
recommendations to recommend against the routine use of
unopposed estrogen for the treatment of chronic conditions
in women who have had a hysterectomy. As with estrogen
and progestin therapy, they cited good evidence for
osteoporosis benefit, but fair evidence for risks associated
with thromboembolism, stroke, lower cognitive function,
and dementia. For women with an intact uterus, unopposed
estrogen is associated with an increased risk of endometrial
cancer (Grady et al 1995).
While the Task Force recommendations provide general
guidance on the use of estrogen with or without a progestin,
there are several clinical considerations that should be
evaluated when weighing the risks and benefits of hormone
replacement therapy (HRT). The Task Force concedes that
while the risks of HRT are statistically significant, the
absolute risk is small. For women aged 50–79 years,
treatment of 10 000 women with HRT for 1 year might result
in 8 additional cases of breast cancer, 8 additional strokes,
8 additional pulmonary emboli, and 7 CHD events, while
resulting in five fewer hip fractures. A woman at high risk
of fracture with a low risk of breast cancer or cardiovascular
disease may consider the benefits of estrogen more
compelling.
In contrast, HRT has not demonstrated superiority with
respect to increased BMD or reductions in fracture risk
compared with bisphosphonates in patients with
osteoporosis. Thus, it should generally not be considered
first line therapy for osteoporosis in bisphosphonate-eligible
individuals, irrespective of the risk-benefit controversies
previously described.
Emerging questions that remain unanswered about
estrogen therapy include the roles of either low-dose or
transdermal formulations in osteoporosis prevention or
treatment. These forms of estrogen therapy were not
evaluated in the large randomized trials upon which much
of the current risk-benefit analysis is based, and are thereforeTherapeutics and Clinical Risk Management 2006:2(3) 290
MacLaughlin et al
not formally associated with the same risks as traditionally
dosed HRT. While there are data demonstrating the efficacy
of these forms in maintaining or improving bone density
(Lindsay et al 2002; Ettinger et al 2004), conclusive evidence
of reduced fracture risk is lacking.
Selective estrogen receptor modulators (SERMs)
For women who are not candidates for bisphosphonate
therapy and in whom the risk of estrogen outweighs the
potential benefits, other options may include selective
estrogen receptor modulators (SERMs). The mechanism of
action for these agents is to act as an estrogen receptor
agonist on bone and uterine tissues, but as an antagonist in
breast tissues (Riggs and Hartmann 2003). Therefore,
SERMs have a similar effect on bone density as estrogen,
but carry a different risk profile.
Raloxifene is the most commonly used SERM for
prevention and treatment of osteoporosis, and is
associated with a 2%–3% increase in BMD (Delmas et
al 1997). Raloxifene has also demonstrated benefits on
vertebral fractures, though data supporting a fracture
benefit at non-vertebral sites is generally lacking. In the
36 month Multiple Outcomes of Raloxifene Evaluation
(MORE) study, raloxifene 60 mg daily given for 3 years
was associated at 30% (NNT=29) reduction in vertebral
fractures (Ettinger et al 1999). The risk of breast cancer
may be as much as 72% lower with raloxifene compared
with placebo (Cauley, Norton, et al 2001). Because
raloxifene is not associated with some of the traditional
side effects of HRT such as breast tenderness and vaginal
bleeding (Ettinger et al 1999), it is not necessarily an
alternative for those women wishing to mitigate some of
the cardiovascular risks of HRT, such as deep vein
thromboembolism, which is increased approximately 1.7–
3-fold compared with placebo (Ettinger et al 1999;
Martino et al 2005). It also does not provide the symptom
relief from hot flushes associated with menopause for
which some women may still elect short term HRT, and
may actually be associated with an increased incidence
(Martino et al 2005).
There is interest in new SERMs for osteoporosis.
Agents such as lasofoxifene, ospemifene, and
bazedoxifene, as well as other novel SERM are in
development. Most are primarily being evaluated for
breast cancer prevention, however data describing their
effects on bone density are emerging (Lasofoxifene 2005;
Ronkin et al 2005; Wurz et al 2005).
Tibolone
Another agent active at the estrogen receptor is tibolone.
Tibolone is a prodrug that must be converted to active
metabolites 3α-hydroxytibolone, 3β-hydroxytibolone, and
a ∆4-isomer, and is available in several countries, though
not the US. Tibolone is classified as a non-estrogen synthetic
steroid which may have estrogenic, progestogenic, or
androgenic effects. In osteoporosis, the effect on trabecular
bone density is thought to be related to activity at the
estrogen receptor (Rubin and Bilezikian 2003).
Tibolone is used for the treatment of postmenopausal
symptoms, and has been evaluated for the prevention and
treatment of osteoporosis. The effects of 1.25–2.5 mg daily
have been studied for improvements in surrogate markers
of bone turnover and bone density improvements at the hip
and lumbar spine. Increases in bone density have ranged
from 3.6% to 7.2% at the lumbar spine and 2.6% to 4.6% at
the femoral neck, though data on fracture reduction is
currently lacking (Thiebaud et al 1998; Pavlov et al 1999;
Rymer et al 2001; Roux et al 2002).
Clear comparisons between tibolone and estrogen
replacement are not available. In one study, the magnitude
of BMD increase was greater with tibolone than with
conjugated equine estrogen/medroxyprogesterone after 3
years (Thiebaud et al 1998). However, in another study the
BMD improvements with tibolone were not superior to
estradiol and norethindrone after 2 years (Roux et al 2002).
These authors did report though, that the incidence of side
effects such as vaginal bleeding and breast tenderness was
lower in the tibolone group. Thus, tibolone may be an
alternative to estrogen in postmenopausal women for the
amelioration of menopausal symptoms, osteoporosis
prevention and possibly for osteoporosis treatment.
However, considering the lack of fracture data, this agent
should not be used first line for osteoporosis prevention or
treatment, particularly in bisphosphonate-eligible women.
Strontium ranelate
Strontium ranelate is a di-strontium salt that has been shown
to act as both a bone-forming and antiresorptive agent (Marie
2005). A proposed mechanism for increased bone formation
is via stimulation of replication of osteoprogenitor cells and
collagen. In addition, strontium has been shown to inhibit
osteoclast activity and differentiation in vitro (Reginster,
Sarlet, et al 2005). It is currently approved in Europe for
the treatment of postmenopausal osteoporosis, though it is
not yet available in the US.Therapeutics and Clinical Risk Management 2006:2(3) 291
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The effects of strontium ranelate on BMD and fractures
have been studied. The strontium ranelate for treatment of
osteoporosis (STRATOS) trial evaluated the effects of 0.5 g,
1 g, or 2 g strontium ranelate compared with placebo over 3
years in 353 postmenopausal women with at least one
previous vertebral fracture and a lumbar T-score <–2.4
(Meunier et al 2002). Lumbar BMD increased in a dose-
dependent manner from a mean annual slope of 1.4% with
0.5 g/day to 3.0% with 2 g/day (p<0.01 for both doses vs
placebo). In a phase 3 study, 1649 postmenopausal women
with osteoporosis and at least one prior vertebral fracture
were given strontium ranelate 2 g/day or placebo and
followed for three years (Meunier et al 2004). The relative
risk of new vertebral fractures decreased 41% compared
with placebo (NNT=9). In the Treatment of Peripheral
Osteoporosis Study (TROPOS), strontium ranelate 2 g/
day or placebo was given to 5091 postmenopausal women
with osteoporosis (Reginster, Seeman, et al 2005). After
a mean follow up of 3 years, nonvertebral fractures were
reduced 16% (NNT=59) and major fragility fractures by
19% (NNT=59) with strontium therapy versus placebo.
Although strontium ranelate has been shown to be
beneficial in postmenopausal osteoporosis, it is not
generally considered a first line agent at this time due to
less clinical experience and fracture data compared with
bisphosphonates.
Sodium fluoride
Although sodium fluoride has been available for several
years, it is not generally considered a routine therapy for
age-related osteoporosis. While sodium fluoride has been
shown to increase BMD by stimulating osteoblastics (Farley
et al 1983), concerns have been raised regarding strength
and quality of new bone formed as well as tolerability. In a
4-year, prospective study of 202 postmenopausal women
with osteoporosis and vertebral fractures who were
randomized to either 75 mg/day of sodium fluoride or
placebo, the incidence of nonvertebral fractures increased
3-fold compared with placebo (Riggs et al 1990). The
postulated mechanism for this increase in fracture is over-
stimulation of bone formation by sodium fluoride, leading
to excessive production of weaker bone. In addition, sodium
fluoride has been associated with other adverse events such
as gastrointestinal disturbances likely as a result of
conversion of sodium fluoride to hydrofluoric acid in the
stomach, and lower extremity pain possibly due to excessive
bone remodeling (Rubin et al 2001).
Due to previously noted adverse effects, systemic sodium
fluoride has not gained wide use or acceptance. However,
more recent data in which sodium fluoride is given on an
intermittent basis and in sustained release form may change
this agent’s place in therapy. Sustained-release sodium
fluoride given on an intermittent basis has been shown to
decrease vertebral fractures and increase BMD (Rubin et al
2001). In a randomized, double-blind, placebo-controlled
trial of 85 postmenopausal women with 1 or more vertebral
compression fractures, 25 mg sustained-release sodium
fluoride given twice daily in 3, 12-week cycles with a 2-
month drug-free period in between was compared with
placebo. After a mean follow up of 42 months, BMD in
L2–L4 increased by 5.4% compared with placebo and
decreased vertebral fractures decreased by 68% (NNT=8).
Thus, while intermittent therapy with sustained release
sodium fluoride may be a viable treatment option for
osteoporosis, it is currently not recommended as a first or
second line therapy due to lack of definitive, long-term data.
Teriparatide (recombinant parathyroid
hormone 1–34)
Parathyroid hormone may be anabolic or catabolic in the
skeleton depending on the mode of administration. When
PTH is given as a once-daily injection, its primary affect is
to increase bone mass (Hodsman et al 2005). The mechanism
by which PTH is thought to stimulate bone production is by
increasing the remodeling rate. PTH increases the amount
of new bone that is laid down in each remodeling unit, which
leads to a net gain in bone mass. In addition, it is also thought
that PTH initially uncouples formation from resorption and
is able to directly stimulate bone formation independent of
resorption (Hodsman et al 2005).
The effects of PTH 1–34 (teriparatide) on BMD and
fractures have been studied. In a placebo controlled study
of 1637 postmenopausal women with at least 1 prior
vertebral fracture, teriparatide 20 mcg and 40 mcg given as
a once-daily subcutaneous injection was compared with
placebo (Neer et al 2001). After a median follow-up of 21
months, teriparatide increased BMD by 9% and 13% in the
lumbar spine and 3 and 6% at the femoral neck compared
with placebo for the 20 mcg and 40 mcg groups respectively.
This increase in BMD lead to a significant decreases in both
vertebral fractures (65% and 69%) and nonvertebral
fractures (53% and 54%) for the PTH groups respectively.
While teriparatide does increase BMD and has been
shown to be effective in reducing the risk of fractures, thereTherapeutics and Clinical Risk Management 2006:2(3) 292
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are significant limitations to its use. First, it must be given
once daily as an injection. Thus, patient acceptance and
adherence to therapy may be significantly diminished,
particularly when compared with an intermittent oral
bisphosphonate regimen. In addition, the extremely high
cost of this agent is also a limitation. Teriparatide is
approximately US$17.50/day (€15/day) for the 20 mcg/day
dose (Selby 2004).
Another limitation of teriparatide may be the slight
increased risk of osteosarcoma. This risk is postulated based
on the induction of osteosarcoma in a rat model. Teriparatide
therapy is not recommended for more than a two year period
and should not be used in patients with an increased risk of
malignancies of the bone (Hodsman et al 2005). Thus,
although teriparatide has been shown to be effective for
osteoporosis, it should generally be reserved for patients
who are unable to tolerate a bisphosphonate and who have
severe/established osteoporosis.
Combination therapy
Use of combination therapies that have different
mechanisms of action is a potential treatment option for
those at high risk for osteoporotic fracture. Data are available
that demonstrate an approximate 1% additional increase in
BMD with combination of a bisphosphonate and estrogen
or raloxifene versus a bisphosphonate alone (Bone et al
2000; Harris et al 2001; Johnell et al 2002; Greenspan et al
2003). However, there are some theoretical concerns that
over-suppression of bone formation may occur with
utilization of two or more antiresorptives, thus potentially
increasing the risk for fractures.
The combination of a bisphosphonate with PTH has had
mixed results. In two randomized, controlled trials, the
combination of alendronate with PTH failed to increase
BMD in men and women (Black et al 2003; Finkelstein et
al 2003). Alendronate attenuation of PTH-induced
stimulation of bone formation was postulated as a potential
etiology for this lack of benefit. However, in the continuation
study by Black et al (2005), patients who were assigned
alendronate for 1 year after receiving 1-year of PTH, BMD
at the lumbar spine increased significantly more in the
combination group (12.1% vs 4.1%). Thus, although fracture
data are not available for the combination of PTH followed
by a bisphosphonate, this may be a reasonable intervention.
Treatment in special populations
As many as 85% of American nursing home residents suffer
from osteoporosis (Zimmerman et al 1999). Comorbidities,
inadequate nutrition, multiple medications, immobility,
difficulty transferring, disabilities, and fragility all contribute
to a much higher fracture rate among nursing home dwelling
elderly as compared with community dwelling elderly.
Osteoporosis treatment and prevention of related fractures
among nursing home residents involves multiple
perspectives including fall prevention, adequate nutrition,
strength and balance training, and frequent medication
review. Environmental modifications to nursing home floors,
doors, and hallways are often the best method to reduce fall
rates and therefore fractures.
Unfortunately, the majority of nursing home residents
with osteoporosis receive inadequate drug therapy. Calcium
and vitamin D supplements are prescribed for approximately
60% of nursing home residents with osteoporosis and only
25% of residents with hip fractures (Kamel 2004).
Bisphosphonate use is also low among nursing home
residents with documented hip fractures. The pharmacologic
foundation for osteoporosis treatment in elderly nursing
home residents should include adequate calcium and vitamin
D supplements and bisphosphonate therapy, taking into
account individual patient considerations such as
swallowing function, mobility/position, and esophageal
function.
Osteoporosis is increasingly recognized as a serious
men’s health issue with 25%–30% of hip fractures occurring
in men (Elliott et al 2004). One in four men over aged 50
will experience an osteoporosis-related fracture in their life
time (NOF 2005b). Male nursing home residents have a 5–
10-fold increase in fracture risk compared with males
residing in the community. Men experience higher morbidity
and mortality after hip fracture with one year mortality post
hip fracture approximately double in men when compared
with women (Amin and Felson 2001). After sustaining a
hip fracture, up to 50% of men require institutional care.
Thus, fall prevention is an important concern for both
community dwelling men and nursing home male residents.
Aged-related osteoporosis in men may be exacerbated by
lifestyle habits including low physical activity, low body
weight, excessive alcohol intake, and smoking. The
pharmacologic foundation for osteoporosis treatment in
men, as well as women, includes adequate calcium and
vitamin D supplementation. First line therapy includes oral
bisphosphonates (eg, alendronate). Teriparatide is indicated
for men with idiopathic or hypogonadism-related (associated
low levels of estradiol and testosterone) osteoporosis who
are at high risk of fracture (Orwoll et al 2003; Teriparatide
2003). Public relations campaigns of the NationalTherapeutics and Clinical Risk Management 2006:2(3) 293
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Osteoporosis Foundation are now directed specifically
toward men to help patients and practitioners understand
that both genders are susceptible to the devastating effects
of age-related bone loss.
Conclusions
Osteoporosis is a significant problem for the global
community. With the aging of the population, osteoporosis
and related fractures will likely continue to increase. Various
interventions are available to decrease the morbidity,
mortality, and economic impact of age-related osteoporosis.
This includes identification of risk factors for low BMD
and falls, screening patients at risk, and instituting
pharmacological therapy for those with documented
osteoporosis. All patients should receive adequate calcium
and vitamin D. Medications which have proven to decrease
factures should be used preferentially over medications for
which there is only positive BMD data. Further research is
needed to determine if combination therapies have additive
effects on fracture reduction. In addition, attention should
be paid to patients who may be at significant risk of age-
related osteoporosis and related fractures, but are often
neglected, such as men and those in the nursing homes.
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